S&P Futures
5,886.25 -10.00 (-0.17%) Dow Futures
43,120.00 -57.00 (-0.13%) Nasdaq Futures
20,472.25 -47.25 (-0.23%) Russell 2000 Futures
2,249.70 -5.80 (-0.26%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,748.30 +9.40 (+0.34%)
Synaptogenix, Inc. (SNPX)
After hours:
- PR Newswire
Synaptogenix Announces $5.0 Million Financing
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common sto
- PR Newswire
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Pate
